No Data
No Data
Werewolf Therapeutics Is Maintained at Market Outperform by JMP Securities
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $4
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Cuts Target Price to $4
Buy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial Position
Express News | Werewolf Therapeutics Inc - Cash Runway Expected Through Q2 2026
Express News | Werewolf Therapeutics Inc - Data From Wtx-124 Combo Trial Expected in Q4 2025